Purple Biotech Ltd ADR(PPBT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 29 at 4:00 AM ET (Korea 9/29 17:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -28.06 | Insider Own | 0.1% | Shs Outstand | 1.6M | Perf Week | 4.2% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | 82.37% | Insider Trans | - | Shs Float | 1.6M | Perf Month | -10.24% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | -2.88 | Inst Own | 5.21% | Short Float | 5% | Perf Quarter | -14.37% |
| Income | -0.02B | P/S | - | EPS this Y | 89.57% | Inst Trans | 17.52% | Short Ratio | 0.06 | Perf Half Y | -62.8% |
| Sales | 0.00B | P/B | 0.2 | EPS next 5Y | 78.99% | ROA | -101.51% | Short Interest | 0.08M | Perf YTD | -77.34% |
| Book/sh | 7.58 | P/C | 0.4 | EPS past 3/5Y | 38.1% 29.92% | ROE | -111.29% | 52W High | -89.43% ($14.10) | Perf Year | -75.15% |
| Cash/sh | 3.77 | P/FCF | - | Sales past 3/5Y | - | ROIC | -200.79% | 52W Low | 28.45% ($1.16) | Perf 3Y | -99.36% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -151.47% | Gross Margin | - | Volatility(W/M) | 8.27% 12.62% | Perf 5Y | -99.84% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.17 | Perf 10Y | -99.98% |
| Dividend Ex-Date | - | Quick Ratio | 3.7 | EPS Q/Q | 110.06% | Profit Margin | - | RSI (14) | 42.39 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.7 | Sales Q/Q | - | SMA20 | -9.75% ($1.65) | Beta | 0.72 | Target Price | $17 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/7 | SMA50 | -4.38% ($1.56) | Rel Volume | 0.01 | Prev Close | $1.51 |
| Employees | 10 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 58.16% - | SMA200 | -59.96% ($3.72) | Avg Volume(3M) | 1.28M | Price | $1.49 |
| IPO | 2015/11/20 | Option/Short | Yes/Yes | Trades | 134 | Volume | 13,442 | Change | -1.32% |
🧬 This is a clinical-stage oncology-focused biotech headquartered in Israel. The company develops immuno-oncology and targeted therapies, and has recently been shifting its business focus toward the trispecific antibody platform CAPTN-3. As a microcap stock with a very small market capitalization, the company is highly volatile, with even a single clinical readout capable of significantly moving the share price.
Over the past 1 year, on the lower side
89% below its 1-year high.
Traded less than usual That is 1% of its average volume.
PPBT has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +89.6% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.8%. The S&P 500 did +77% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 5.2%.
Tap to view numbers
It ranks #580 of 592 in the industry
Based on market cap of $2M.
MTNB#579 Matinas Biopharma Holdings Inc $2M PER - PPBT#580 Purple Biotech Ltd ADR $2M PER - 
VBIO#581 Valion Bio Inc $2M PER - 
ARTL#582 Artelo Biosciences Inc $2M PER - 
GNPX#583 Genprex Inc $2M PER - 
FAQ
What kind of company is PPBT?
PPBT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PPBT?
The market cap of PPBT is approximately $2M, ranking 5,828 within its sector.
What is the 52-week high and low for PPBT?
PPBT has recorded a 52-week high of $14.10 and a low of $1.16.
